Skip to content

Contingency Management for Attendance - 2

Contingency Management for Attendance

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00249639
Enrollment
300
Registered
2005-11-07
Start date
2004-01-31
Completion date
2006-01-31
Last updated
2017-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Substance Abuse

Keywords

Contingency Management, Substance Abuse Treatment

Brief summary

The purpose of this study is to evaluate the effectiveness of a low-cost contingency management procedure as compared to standard treatment. Using a cross-over design, CM is implemented at different community-based clinics and compared with non-CM in the same facilities. Research staff collects information regarding patients' demographic characteristics, attendance, and outcomes at the clinics. During Phase A (non-CM), standard clinical practice is in place. During Phase B (CM), all patients have the chance to win prizes by coming to treatment. Each participating clinic is randomly assigned to receive either the A or B phase first; each phase is in effect for 16 weeks.

Interventions

BEHAVIORALContingency management

Rewards valued $1-$100

Sponsors

UConn Health
CollaboratorOTHER
National Institute on Drug Abuse (NIDA)
Lead SponsorNIH

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Subjects will be patients in treatment at one of the participating clinics during the study period. There are no other inclusion or

Exclusion criteria

because we wish to make enrollment open to increase generalizability.

Design outcomes

Primary

MeasureTime frame
Drug usebaseline and each follow-up
Retentionbaseline and each follow-up

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026